# A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection

> **NCT06635798** · PHASE3 · RECRUITING · sponsor: **Genrix (Shanghai) Biopharmaceutical Co., Ltd.** · enrollment: 582 (estimated)

## Conditions studied

- Tetanus

## Interventions

- **BIOLOGICAL:** GR2001
- **BIOLOGICAL:** HTIG

## Key facts

- **NCT ID:** NCT06635798
- **Lead sponsor:** Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-03
- **Primary completion:** 2024-12-04
- **Final completion:** 2025-03-04
- **Target enrollment:** 582 (ESTIMATED)
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06635798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06635798, "A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06635798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*